iving Well With Diabetes: an open-label, single-arm trial of team-based transition to insulin in primary care to improve HbA1c for patients with poorly controlled type 2 diabetes

Tongan Health Society Inc.0 个研究点目标入组 254 人开始时间: 2019年6月12日最近更新: 2019年7月15日

适应症

试验速览

暂无简介。

•1. T2D patients who are insulin-naive.
•2. At least 2 oral hypoglycaemic agents (OHA) (eg. metformin, sulphonylurea, TZDs, DPP-4 inhibitor) at maximal tolerated doses, or in the opinion of the responsible medical practitioner, insulin is deemed necessary.
•3. Doses of the OHAs should be stable for at least 3 months prior to enrollment into the study (or medical practitioner discretion).
•4. HbA1c>=7.5% in the last 6 months who are on maximum oral hypoglycaemic agents
•5. T2D patients willing to monitor glucose levels at least twice daily

•1. Type 1 diabetes
•2. Previous or current treatment with insulin (excluding the short term (<2 weeks) use of insulin in acute illness or during hospitalization)
•3. Significant cognitive impairment
•4. Impaired vision or any other physical handicap precluding reliable glucose monitoring administration of insulin
•5. Significant renal impairment (eGFR < 20)
•6. Any life-threatening illness
•7. Pregnancy or planned pregnancy
•8. Breastfeeding
•9. Major psychiatric disorder
•10. Substance misuse (alcoholism, drug addiction, etc)

发起方

Tongan Health Society Inc.